San Diego, California-based Arena Pharmaceuticals Inc.'s stock fell 5.98%, to finish Wednesday's session at $1.73 with a total volume of 1.06 million shares traded. Over the last one month and the previous three months, shares of Arena Pharma, which discovers, develops, and commercializes novel drugs that target G protein-coupled receptors to address unmet medical needs in the US and South Korea, have gained 15.33% and 6.13%, respectively. The stock is trading 3.01% and 2.06% above its 50-day and 200-day moving averages, respectively. Arena Pharmaceuticals' stock has a Relative Strength Index (RSI) of 47.50.
On September 15th, 2016, research firm FBR & Co. initiated an 'Outperform' rating on the Company's stock, issuing a target price of $6 per share. Free research report on ARNA is available at:
Tarrytown, New York-based Progenics Pharmaceuticals Inc.'s stock dropped 4.72%, to close the day at $6.26. The stock recorded a trading volume of 810,276 shares. Shares of Progenics Pharma, which develops medicines for oncology in the US and internationally, have gained 3.13% in the last one month, 29.61% in the previous three months, and 13.82% in the past one year. The Company's shares are trading above its 200-day moving average by 20.28%. Additionally, the stock has an RSI of 44.45. The complimentary research report on PGNX can be downloaded at:
On Wednesday, shares in Richmond, California headquartered Sangamo Biosciences Inc. ended the session 8.22% lower at $4.13 with a total volume of 939,814 shares traded. Shares of Sangamo Biosciences, which focuses on the research, development, and commercialization of engineered DNA-binding proteins for therapeutic genome editing and gene regulation, are trading 11.16% and 29.33% below its 50-day and 200-day moving averages, respectively. Moreover, shares of the Company have an RSI of 37.67. Visit us today and access our complete research report on SGMO at:
On Wednesday, shares in Cambridge, Massachusetts headquartered Alnylam Pharmaceuticals Inc. recorded a trading volume of 2.36 million shares, which was higher than their three months average volume of 1.01 million shares. The stock ended the day 2.67% higher at $35.76. Shares of Alnylam Pharma, which discovers, develops, and commercializes novel therapeutics based on RNA interference, are trading below its 50-day and 200-day moving averages by 49.00% and 46.33%, respectively. Furthermore, Alnylam Pharma's shares have an RSI of 19.42.
On October 7th, 2016, research firm Morgan Stanley downgraded the Company's stock rating from 'Overweight' to 'Equal-Weight'. Get free access to your research report on ALNY at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA